Cancer is defined as the abnormal growth of cells in the body. Cells located at any part of the body can turn cancerous and spread to other parts of the body. Liver cancer begins in the cells of the liver. Several kinds of cancer can form in the liver. Hepatocellular carcinoma is considered to be the most common liver cancer and begins in the hepatocyte. Other types of liver cancer include hepatoblastoma and intrahepatic cholangiocarcinoma. These are considered to be less common. According to the American Society of Clinical Oncology (ASCO), around 80% of adult primary liver cancers are hepatocellular carcinomas. Liver cancer diagnostics include techniques used for liver cancer identification and confirmation.
According to the World Cancer Research Fund, in 2018, nearly 840,000 new cases of liver cancer were diagnosed globally. Liver cancer is considered to be the fifth most common cancer among men and the ninth most common cancer among women. According to the Centers for Disease Control and Prevention (CDC), around 33,000 people are diagnosed with liver cancer in the U.S. every year, and about 26,000 people succumb to the disease. The percentage of people in the U.S. suffering from liver cancer has been increasing for several decades. According to the Department of Health in New York State, nearly 1,500 men and 600 women are diagnosed with liver cancer every year. Approximately 900 men and 500 women in New York succumb to liver cancer each year.
Rise in prevalence of liver cancer, high alcohol consumption, research & development activities including development of newer techniques for the diagnosis of liver cancer, availability of efficient cancer treatments, and rise in adoption of new techniques for detection of liver cancer are anticipated to boost the global liver cancer diagnostics market. However, the shortage of skilled professionals and lack of awareness about the technological advancements are expected to hamper the growth of the liver cancer diagnostics market.
In terms of screening type, the global liver cancer diagnostics market can be segmented into laboratory tests, endoscopy, imaging, biopsy, and others. The laboratory tests segment can be bifurcated into biomarkers and blood tests. The laboratory tests segment is anticipated to account for the largest market share during the forecast period, attributed to increasing in a requirement for effective diagnostic tests for hepatocellular carcinoma. The biomarkers segment can be divided into molecular markers, oncofetal & glycoprotein antigens, pathological biomarkers, growth factors & receptors, and enzymes & isoenzymes. In terms of end-user, the liver cancer diagnostics market can be categorized into hospital associated laboratories, independent diagnostic laboratories, and others. The hospital associated laboratories segment is anticipated to account for the largest share of the global liver cancer diagnostics market, owing to an increase in the number and well-equipped infrastructure of hospitals.
In terms of region, the global liver cancer diagnostics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global liver cancer diagnostics market due to technological advancements, increase in demand for care diagnostics, and rapid adoption of novel diagnostics and therapeutic approaches. The liver cancer diagnostics market in the Asia Pacific is anticipated to witness strong growth, attributed to increases in population, a rise in prevalence of liver cancer, surge in initiatives by a government in health care, increase in research and development activities.
Key players operating in the global liver cancer diagnostics market are Illumina, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN, Siemens Healthcare Private Limited, Danaher, Foundation Medicine, Inc., Biocept, Inc., Koninklijke Philips N.V., and Hologic, Inc. These players have adopted strategies such as partnerships, agreements, collaborations, partnerships, and new product development to gain a competitive advantage in the global liver cancer diagnostics market.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- The Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates are included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.